998. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
作者: William D Tap.;Robin L Jones.;Brian A Van Tine.;Bartosz Chmielowski.;Anthony D Elias.;Douglas Adkins.;Mark Agulnik.;Matthew M Cooney.;Michael B Livingston.;Gregory Pennock.;Meera R Hameed.;Gaurav D Shah.;Amy Qin.;Ashwin Shahir.;Damien M Cronier.;Robert Ilaria.;Ilaria Conti.;Jan Cosaert.;Gary K Schwartz.
来源: Lancet. 2016年388卷10043期488-97页
Treatment with doxorubicin is a present standard of care for patients with metastatic soft-tissue sarcoma and median overall survival for those treated is 12-16 months, but few, if any, novel treatments or chemotherapy combinations have been able to improve these poor outcomes. Olaratumab is a human antiplatelet-derived growth factor receptor α monoclonal antibody that has antitumour activity in human sarcoma xenografts. We aimed to assess the efficacy of olaratumab plus doxorubicin in patients with advanced or metastatic soft-tissue sarcoma.
|